Cancer Res Treat.  2004 Dec;36(6):367-371.

The Efficacy of Docetaxel and Cisplatin Combination Chemotherapy for the Treatment of Advanced Gastric Cancer after Failing to 5-Fluorouracil Based Chemotherapy

• Shin SJ
• Kim MK
• Lee KH
• Hyun MS
• Kim SW
• Song SK
• Bae SH
• Ryoo HM

Abstract

PURPOSE
This study was conducted to confirm the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy (DP) in patients with advanced gastric cancer. MATERIALS AND METHODS: Patients with measurable gastric adenocarcinoma received intravenous docetaxel 75 mg/m2 and cisplatin 75 mg/m2 with premedication on day 1, which was repeated every 3 weeks. All patients received DP as a second-line treatment after failing to 5-FU based chemotherapy. RESULTS: 34 patients were enrolled in this study between January 1998 and August 2003. A total of 112 cycles (median 3 cycles) were administered. Responses were evaluable in 30 patients. The objective response rate was 16.7% (95% CI: 3.5~30.3), with a stable disease in 56.7% (95% CI: 40.0~74.4) and a progressive disease in 26.7% (95% CI: 10.9~42.5) of patients, with a median follow up duration of 20 months for all the patients, The median duration of response, time to progression and overall survival were 2.1 months (95% CI: 0.4~3.9), 4.2 months (95% CI: 2.3~6.1) and 6.8 months (95% CI: 1.3~12.3), respectively, with a 1-year survival rate of 32%. The toxicity was evaluated in 30 patients, with neutropenia being most common. Renal impairment was seen in two patients with grade 3 creatinine elevation and liver enzyme elevation in four with grades 3 and 4. CONCLUSION: Although DP was an active combination regimen, with a tumor control rate of about 73% and with moderate tolerance, adjustment of the administration schedule, with further evaluation of other combination chemotherapies of docetaxel with new agents, other than cisplatin, seem warranted.

Keyword

Stomach neoplasm; Cisplatin; Docetaxel

MeSH Terms

Adenocarcinoma
Appointments and Schedules
Cisplatin*
Creatinine
Drug Therapy*
Drug Therapy, Combination*
Fluorouracil*
Follow-Up Studies
Humans
Liver
Neutropenia
Premedication
Stomach Neoplasms*
Survival Rate
Cisplatin
Creatinine
Fluorouracil

Figure

• 

  Fig. 1 Overall survival and time to progression in the treated population.

Reference

1. World Health Report 1998: A Vision for All. 1998. Geneva, Switzerland: World Health Organization.

2. Clarke JS, Cruze K, El Farra S, Longmire WP Jr. The natural history and results of surgical therapy for carcinoma of the stomach: an analysis of 250 cases. Am J Surg. 1961; 102:143–152. PMID: 13693893.

3. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997; 8:163–168. PMID: 9093725.

4. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs. fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA. 1985; 253:2061–2067. PMID: 2579257.

5. Macdonald JS, Schein PS, Woolley PV, Smythe T, Ueno W, Hoth D, et al. 5-Fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med. 1980; 93:533–536. PMID: 7436184.

6. Kulke MH. The treatment of advanced gastric cancer: in search of the right combination. J Clin Oncol. 2000; 18:2645–2647. PMID: 10894862.

7. Tanaka M, Obata T, Sasaki T. Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo. Eur J Cancer. 1996; 32A:226–230. PMID: 8664032.

8. Crown J, O'Leary M. The taxanes: an update. Lancet. 2000; 355:1176–1178. PMID: 10791395.

9. Vanhoefer U, Harstrick A, Wilke H, Achterrath W, Preusser P, Staho M. Phase II study of docetaxel (D) as salvage chemotherapy in patients with advanced gastric cancer. Eur J Cancer. 1999; 35(Suppl 4):145. PMID: 10211103.

10. Roth AD, Maibach R, Martinelli N. Taxotere-cisplatin in advanced gastric carcinoma (gastric cancer): an active drug combination. Proc Annu Meet Am Soc Clin Oncol. 1998; 17:283.

11. Saitoh S, Sakata Y. Docetaxel and cisplatin in patients with advanced gastric cancer: results of Japanese phase I/II study. Gastric Cancer. 2002; 5(Suppl 1):23–26. PMID: 12772883.

12. Mitachi Y, Sakata Y, Ohtsu A, Hyodo I, Katsu K, Sirenji M, et al. Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer: a multicenter pahse I/II study. Gastric Cancer. 2002; 5:160–167. PMID: 12378343.

13. Bokemeyer C, Hartmann JT, Lampe CS, Clemens MR, Quietzsch D, Forkmann L, et al. Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer. Semin Oncol. 1997; 24:S19-96–S19-100. PMID: 9427277.

14. Boku N, Ohtsu A, Shimada Y, Shirao Y, Seki S, Saito H, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol. 1999; 17:319–323. PMID: 10458249.

15. Murad AM, Petroianu A, Guimaraes RC, Aragao BC, Cabral LO, Scalabu A, et al. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. Am J Clin Oncol. 1999; 22:580–586. PMID: 10597742.

16. Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, et al. A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer. 2000; 83:458–462. PMID: 10945491.

17. Ridwelski K, Gebauer T, Fahlke J, Kroning H, Kettner E, Meyer F, et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol. 2001; 12:47–51. PMID: 11249048.

18. Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol. 1998; 16:3362–3368. PMID: 9779713.

19. Kim YT, Sohn JH, Kim SH, Rha SY, Kim C, Roh JK, et al. Infusional 5-Fluorouracil, leucovorin and docetaxel in advanced gastric cancer. Cancer Res Treat. 2003; 35:123–129.

20. Chung JH, Bae YZ, Kim SH, Moon CH, Chung JY, Kwon HC, et al. Salvage treatment of advanced gastric cancer using FEP (5-FU, Etoposide, Cisplatin) combination chemotherapy. Cancer Res Treat. 2002; 34:382–387.

21. Roth AD, Maibach R, Martinelli N, Fazio N, Aapro MS, Pagani O, et al. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Ann Oncol. 2000; 11:301–306. PMID: 10811496.

22. Andre T, Louvet C, Ychou M. Docetaxel-epirubicine as second-line treatment for patients with advanced gastric cancer. Proc Am Soc Clin Oncol. 1999; 18:1062. (Abstr).

23. Giuliani F, Gebbia V, De Vita F, Maiello E, Gebbia N, Paoletti G, et al. Docetaxel (taxotere) as salvage chemotherapy in patients with advanced gastric cancer. A phase II study of the Southern Italian Oncology Group (GOIM). Ann Oncol. 2000; 11(Suppl 4):67. (Abstr).

24. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, et al. Docetaxel administered on a weekly basis for the metastatic breast cancer. J Clin Oncol. 2000; 18:1212–1219. PMID: 10715290.